Skip to search formSkip to main contentSkip to account menu

NSC-26980

Known as: NSC 26980, NSC26980 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Mitomycin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1976
1976
Neurotoxicity from 5-fluorouracil (NSC-19893) administration reproduced by mitomycin C (NSC-26980).
Review
1974
Review
1974
Phase I-II evaluation of weekly mitomycin-C (NSC-26980) for patients with metastatic GI and breast malignancies.
The experience of Mitomycin-C given as a once weekly intraveneous injection for carcinoma of gastroenteric and breast origin with… 
1971
1971
Evaluation of dosage schedules of mitomycin C (NSC-26980) in children.
1971
1971
Evaluation of a combination of mitomycin C (NSC-26980), phenylalanine mustard (NSC-14210), and vincristine (NSC-67574) in the treatment of osteogenic sarcoma.
1970
1970
Clinical experience with mitomycin C (NSC-26980).
1970
1970
Clinical experience with mitomycin C (NSC-26980).
1969
1969
Evaluation of mitomycin C (NSC-26980) in the treatment of metastatic osteogenic sarcoma.
1969
1969
Clinical study of mitomycin C (NSC-26980) in colorectal cancer.
Highly Cited
1968
Highly Cited
1968
Mitomycin C therapy in advanced gastrointestinal cancer.
Mitomycin C (NSC-26980) is a chemotherapeutic agent capable of producing objective regressions in gastrointestinal cancer at a… 
1968
1968
Effects of mitomycin c (NSC-26980) in 346 patients with advanced cancer. Eastern Clinical Drug Evaluation Program.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)